Editorial illustration
President Trump confirmed Tuesday that FDA Commissioner Dr. Marty Makary is stepping down, marking another shakeup in the administration’s health policy team. Kyle Diamantas, the FDA’s food chief, will step in as acting commissioner while the search for a permanent replacement begins.
“Marty is a terrific guy, but he’s going to go on and he’s going to lead a good life,” Trump told reporters outside the White House. “He was having some difficulty.” The president noted that the deputy would take over temporarily until a new leader is found.
The move comes after months of tension behind the scenes. According to a senior administration official who spoke with Politico, the decision was “months in the making” and was ultimately driven by Health and Human Services Secretary Robert F. Kennedy Jr., with Trump’s approval.
Makary, a former Johns Hopkins professor, initially seemed like a promising pick for conservatives who remembered his willingness to challenge the COVID establishment. He gained national attention for pushing back against lockdown orthodoxy and questioning the single-minded focus on vaccines as the only solution. His appointment signaled that Trump was serious about bringing fresh thinking to federal health agencies.
But the honeymoon didn’t last. Makary’s tenure was plagued by internal conflicts, mass layoffs, and policy battles that pitted him against lawmakers, pharmaceutical companies, and even the president himself. The breaking point appears to have been the ongoing fight over abortion pills, an issue where Makary’s position increasingly clashed with the administration’s base.
During the 2024 campaign, Trump made clear he wouldn’t reverse Biden’s refusal to enforce federal laws against mailing abortion pills across state lines. That stance put him at odds with pro-life advocates who expected more aggressive action. Makary’s handling of the issue only added fuel to the fire.
What happens next at the FDA matters. The agency oversees everything from drug approvals to food safety, and its decisions ripple through the entire healthcare system. With RFK Jr. now driving personnel decisions, we may see an even sharper break from the agency’s traditional approach. The question is whether the next commissioner will clean house more thoroughly or get bogged down in the same bureaucratic quicksand that swallowed Makary.
For conservatives who wanted to see real reform at the FDA, this is a moment of opportunity. But it’s also a reminder that changing Washington requires more than appointing the right people. It takes relentless pressure, clear priorities, and a willingness to fight the permanent bureaucracy that resists accountability at every turn. Trump has shown he’s willing to make changes when things aren’t working. Now we’ll see if the next pick can get results where Makary fell short.
About The Author
